Integrated morphologic, immunophenotypic, and molecular profiling of advanced upper tract urothelial carcinoma across tumor compartments supports biopsy-based testing.

doi:10.1016/j.prp.2026.156642

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrated morphologic, immunophenotypic, and molecular profiling of advanced upper tract urothelial carcinoma across tumor compartments supports biopsy-based testing.

Pathology, research and practice - 1 Nov 2026

Martelli Filippo Maria, Fanelli Giuseppe Nicolò, Stefanizzi Lavinia, Vicentini Caterina, Marcolini Lisa, Marletta Stefano, Giacometti Cinzia, Bertoloni Rossella, Bertoldi Nicole, Salvagno Gian Luca, Caliò Anna, Martignoni Guido

Abstract excerpt

Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with limited molecular characterization in advanced disease. FGFR3 alterations are well established in low-grade urothelial carcinoma, but their prevalence, stability, and biological significance in locally advanced and metastatic UTUC remain only partially defined. We performed an integrated morphologic, immunohistochemical, and molecular...

Read the complete abstract on PubMed

Topics

Humans
Female
Male
Receptor, Fibroblast Growth Factor, Type 3
Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Carcinoma, Transitional Cell

Biomarkers, Tumor

Middle Aged

Immunohistochemistry

Immunophenotyping

Aged, 80 and over

Biopsy

Urologic Neoplasms

Mutation

Adult

Source

Open in PubMed

Identifiers

PMID: 42566915
DOI: 10.1016/j.prp.2026.156642

Genes

FGFR3
GATA3
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated morphologic, immunophenotypic, and molecular profiling of advanced upper tract urothelial carcinoma across tumor compartments supports biopsy-based testing.PMID 42566915Read ↗

Detection of FGFR Alterations in Urothelial Carcinoma: Current Diagnostic Methodologies, Technical Considerations and Future Perspectives.Semantic proximity Read ↗

Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations.Semantic proximity Read ↗

Molecular classification and diagnostics of upper urinary tract urothelial carcinoma.Semantic proximity Read ↗

Genomic Characterization of Upper Tract Urothelial Carcinoma.Semantic proximity Read ↗

Nested and Large Nested Subtypes of Urothelial Carcinoma of the Upper Urinary Tract: A Multi-institutional Study.Semantic proximity Read ↗

FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting.Semantic proximity Read ↗

Current Knowledge on Genomic Profiling of Upper Tract Urothelial CarcinomaSemantic proximity Read ↗

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.Semantic proximity Read ↗

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.Semantic proximity Read ↗

FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation SequencingSemantic proximity Read ↗

Reflex somatic testing for the detection of FGFR alterations in urinary tract carcinomas: A dual-institutional experience.Semantic proximity Read ↗

Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.